Navigation Links
Vanda Pharmaceuticals Reports First Quarter 2013 Results
Date:5/9/2013

ries not covered by a third party development and commercialization agreement.

Vanda plans to initiate a proof of concept study for VLY-686 in Treatment Resistant Pruritus in Atopic Dermatitis in the second half of 2013.  VLY-686 is a small molecule neurokinin-1 receptor (NK-1R) antagonist currently at the clinical stage of development.  An inappropriate NK-1R activation either in nervous tissue or peripherally could result in pathological conditions such as substance dependence, anxiety, nausea/vomiting, and pruritus.  An NK-1R antagonist may possess the ability to reduce this over-stimulation of the NK-1R, and as a result address the underlying pathophysiology of the symptoms in these conditions.

During the first quarter of 2013, Vanda withdrew its MAA submitted to the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) for Fanaptum™  for the treatment of adult patients with schizophrenia.  This withdrawal was based on a request by the CHMP/Rapporteur/Co-rapporteur for Vanda to submit the results from an ongoing relapse prevention, randomized iloperidone-placebo withdrawal study in patients with schizophrenia.  The results of this study will not be available in the timeframe allowed by the EMA's Centralised Procedure.  Vanda intends to reassess its European regulatory strategy for Fanaptum™ once the results from the Relapse Prevention Study in Patients with Schizophrenia (REPRIEVE) being conducted by Novartis, become available. 

Vanda recorded first quarter 2013 revenue of $8.1 million including Fanapt® royalties of $1.5 million.  Fanapt® prescriptions, as reported by IMS, were approximately 38,900 for the first quarter of 2013.  This represents a 9% increase over first quarter 2012 prescriptions and a 2% increase versus fourth quarter 2012 prescriptions.On April 18, 2013, Vanda announced that Paolo Baroldi, M.D., Ph.D. joined its mana
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Vanda Pharmaceuticals Appoints Dr. Paolo Baroldi As Chief Medical Officer
2. Nieuwe behandeloptie vandaag geïntroduceerd voor artsen die patiënten behandelen met veelvuldig recidiverend of refractair agressief B-cel-non-hodgkinlymfoom
3. Vanda Pharmaceuticals to Present at the Lazard Healthcare Conference
4. Questcor Pharmaceuticals to Present at Bank of America Merrill Lynch 2013 Healthcare Conference
5. Adamis Pharmaceuticals CEO Provides Update for Shareholders
6. Cadence Pharmaceuticals Reports First Quarter 2013 Financial Results
7. Valeant Pharmaceuticals Announces Extension of the Expiration Date for Its Previously Announced Tender Offer for All Outstanding Shares of Common Stock of Obagi Medical Products, Inc.
8. VentiRx Pharmaceuticals Appoints James Kyle Bryan, M.D. as Chief Medical Officer
9. Aurigenes Collaboration Programs with Endo Pharmaceuticals Reach Important Milestones
10. Next Silicon Valley BioTalks Tackles “Is EDC Becoming a Commodity?” at Onyx Pharmaceuticals HQ
11. Global Nuclear Medicine / Radiopharmaceuticals Market worth $5.55 Billion by 2017
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... April 1, 2015 Synthetic Biologics, Inc. ... for serious infections and diseases, with a focus ... data supporting the development of SYN-004, the Company,s ... (IV) antibiotics within the gastrointestinal (GI) tract and ... for the prevention of C. difficile ...
(Date:4/1/2015)... Holomic is introducing the HRDR-400, the first ... fluorescent rapid tests with one device. , Holomic ... and is already selling its HRDR-200 chromatographic and HRDR-300 ... its kind offering for manufacturers and end-users that need ... Karlovac, CEO of Holomic LLC, commented, "We are responding ...
(Date:4/1/2015)... 2015  Spherix Incorporated (Nasdaq: SPEX ) -- an ... and monetization of intellectual property, today announced that ... service global investment bank specializing in micro, small, ... featuring Spherix. The report, authored by ... at Chardan, was published on March 31, 2015. ...
(Date:4/1/2015)... WASHINGTON and NEW YORK CITY ... As a leading provider of market research reports ... BioInformant Worldwide, LLC, indicating that 2015 will be a year ... For executives operating a stem cell company or ... a difficult task. You must analyze market conditions, predict industry ...
Breaking Biology Technology:Synthetic Biologics' SYN-004 Clinical Data for Protection of Microbiome Selected for Poster Presentation at American Society of Microbiology 2015 2Synthetic Biologics' SYN-004 Clinical Data for Protection of Microbiome Selected for Poster Presentation at American Society of Microbiology 2015 3Synthetic Biologics' SYN-004 Clinical Data for Protection of Microbiome Selected for Poster Presentation at American Society of Microbiology 2015 4Holomic to Introduce the First Dual, Chromatographic and Fluorescent Rapid Test Reader, the HRDR-400 2Chardan Capital Issues Industry Note Covering Spherix 2Chardan Capital Issues Industry Note Covering Spherix 3MarketResearch.com: "Blockbuster" Year for Stem Cells Creates Market Opportunities, Says BioInformant Worldwide Report 2MarketResearch.com: "Blockbuster" Year for Stem Cells Creates Market Opportunities, Says BioInformant Worldwide Report 3MarketResearch.com: "Blockbuster" Year for Stem Cells Creates Market Opportunities, Says BioInformant Worldwide Report 4
... DIEGO, Sept. 13 Genomatica announced today ... the company full time as executive chairman and chief ... with leading chemical producers, users, feedstock suppliers, brands and ... and biotech leadership; $500 million in partnerships ...
... Convergent Procedure, a novel approach to treat atrial ... nContact Surgical, Inc. (nContact), was highlighted at the ... Association for Cardio-Thoracic Surgery) Annual Meeting in Geneva, ... 2010 Techno-College Programme to receive an update on ...
... Berkeley, have developed a pressure-sensitive electronic material from semiconductor ... the term "thin-skinned." "The idea is to ... which means incorporating the ability to feel and touch ... and computer sciences and head of the UC Berkeley ...
Cached Biology Technology:Bill Baum Joins Genomatica as it Ramps for Commercial Rollout 2Bill Baum Joins Genomatica as it Ramps for Commercial Rollout 3Bill Baum Joins Genomatica as it Ramps for Commercial Rollout 4The Convergent Procedure for the Treatment of Chronic Atrial Fibrillation Highlighted at EACTS Annual Meeting in Geneva 2Engineers make artificial skin out of nanowires 2Engineers make artificial skin out of nanowires 3
(Date:3/31/2015)...  Elephant Talk Communications Corp. (NYSE MKT: ETAK) ("Elephant ... Defined Network Architecture (ET Software DNA® 2.0) platforms and ... $20.4 million for the year ended December 31, 2014 ... year ended December 31, 2013. At ... its multi-year transition away from its legacy landline business ...
(Date:3/31/2015)... YORK , March 31, 2015   Guidepoint ... the launch of the Post-Surgical Pain Management TRACKER, part ... products tracking usage trends in the medical device and ... access to data including treatment volumes, market share, and ... the pain associated with joint surgery. The ...
(Date:3/30/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/lc9bnl/global_gesture ... Gesture Recognition Market in Automotive Sector 2014-2018" report ... Global Gesture Recognition market in Automotive Sector to grow ... Gesture recognition is the ability of a ... an individual. Gesture recognition technology can be 2D-based or ...
Breaking Biology News(10 mins):Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2
... Researchers at the RIKEN Plant Science Center (PSC) have ... in the model plant Arabidopsis protects cells from harmful ... the journal PLoS Genetics , the finding contributes ... biological processes in both plants and animals, opening the ...
... seals often encounter murky water that impedes their vision; ... Extending their vibration-sensitive whiskers, the mammals are almost as ... if guided by sight. Wolf Hanke and his colleagues ... how harbour seals perceive the world through their flow-sensitive ...
... 2011 UT Southwestern Medical Center researchers have discovered a ... to a treatment to keep cancer cells from spreading. ... 1 (Rasip1) is so specific and central to so many ... form, said Dr. Ondine Cleaver, assistant professor of molecular biology ...
Cached Biology News:Discovery of DNA silencing mechanism reveals how plants protect their genome 2Seals sense shapes using their whiskers to feel wakes 2UT Southwestern researchers find protein that might be key to cutting cancer cells' blood supply 2